Narrative review assesses effectiveness of novel nicotine products and emerging drugs for cessation in nicotine users, highlighting implications for public health.
Key Points
This review aims to evaluate the effectiveness of modern nicotine delivery systems and pharmaceuticals in aiding tobacco cessation.
A comprehensive review of research articles, clinical trials, and drug approvals from databases such as PubMed and Wiley.
Utilized Python tools including Anaconda3 and ShinyWeb App for literature analysis.
Key elements include product evolution and cessation behavior associated with various nicotine aids.
E-cigarettes and snus were found to have limited cessation benefits and are not recommended as sole cessation tools.
Cytisine demonstrated cessation outcomes comparable to established pharmaceuticals like varenicline.
Evidence supporting the efficacy of modern nicotine products as standalone cessation aids was deemed insufficient.